We are developing CMD-501 for the treatment of neuroblastoma and small cell lung cancer. CMD-501 is an autologous cell therapy which utilizes our natural killer T (NKT) cell platform technology in combination with genetically engineered chimeric antigen receptors (CARs) and secretion of the IL-15 cytokine to sustain the activity of the therapeutic cells within the immunosuppressive tumor microenvironment. A Phase 1 trial evaluating CMD-501 for safety and activity in pediatric patients with neuroblastoma is being sponsored and conducted by Baylor College of Medicine (BCM) at Texas Children’s Hospital in Houston, TX

Eligible patient population

Neuroblastoma – Neuroblastoma affects around 1,600 children each year in the United States1 and Europe2 combined.  Similar incidence rates are observed in other regions of the developed world.

The development of CMD-501

We are developing CMD-501 in neuroblastoma as the lead indication and proof of concept.  We will then broaden the application of CMD-501 to the lung cancer indication.

The BCM GINAKIT2 Phase 1 clinical trial is evaluating CMD-501 (CAR.GD2-IL-15 NKTs), a new cancer immunotherapy that uses natural killer T (NKT) cells, in children with neuroblastoma. This study will be the first to use genetically engineered NKT cells in humans.

Information on the clinical trial can be found here: